{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:52:44Z","timestamp":1776750764880,"version":"3.51.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is one of the most common malignant tumors in women worldwide. Histamine (HIS) has been associated with either pro-tumor or anti-tumor effects, depending on the receptor evaluated. It exerts its physiological and pharmacological functions through four receptors (H1R-H4R). In breast cancer, it promotes tumor growth by activating H1 and H2 receptors. Furthermore, HIS released into the tumor microenvironment can promote inflammation associated with tumor development and immunosuppression of the immune response. Several years ago, breast cancer was shown to express the H4R, although conflicting data exist; its activation is associated with tumor progression and the development of metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      In this study, using a murine model of breast cancer with the 4T1 cell line, we investigated in depth the role of H4R in tumor progression. We demonstrated that H4R blockade with the specific antagonist JNJ777120 (JNJ) inhibits tumor cell line proliferation, migratory capacity, and ROS production, while increasing lactate release and rapidly and transiently ERK kinase activation.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , the antitumorigenic effect of JNJ appears to depend on the adaptive immune response, as suggested by the rapid recruitment of CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells, the increased lymphocyte proliferation from JNJ-treated tumors, and the absence of activity in the adaptive immune-deficient Rag1 mice. Moreover, tumor-derived cells showed altered energy metabolism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, our results demonstrate the dual role of HIS via the H4R in 4T1 cells, modulating not only tumor cell development but also the immune microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1770957","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:50Z","timestamp":1776749630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Ramiro","family":"V\u00e1zquez","sequence":"first","affiliation":[{"name":"Laboratorio de CPA y respuesta inflamatoria, Instituto de Medicina Experimental (IMEX)-Conicet, Academia Nacional de Medicina, Pacheco de Melo 3081 (CP1425AU)","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Saibene","sequence":"additional","affiliation":[{"name":"Laboratorio de CPA y respuesta inflamatoria, Instituto de Medicina Experimental (IMEX)-Conicet, Academia Nacional de Medicina, Pacheco de Melo 3081 (CP1425AU)","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Emilia","family":"Boix","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA (INBIRS) Facultad de Medicina, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Maio","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA (INBIRS) Facultad de Medicina, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Salamone","sequence":"additional","affiliation":[{"name":"Laboratorio de CPA y respuesta inflamatoria, Instituto de Medicina Experimental (IMEX)-Conicet, Academia Nacional de Medicina, Pacheco de Melo 3081 (CP1425AU)","place":["Buenos Aires, Argentina"]},{"name":"Departamento de Inmunolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Balboa","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA (INBIRS) Facultad de Medicina, Universidad de Buenos Aires - Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]},{"name":"Departamento de Inmunolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Laboratorio de CPA y respuesta inflamatoria, Instituto de Medicina Experimental (IMEX)-Conicet, Academia Nacional de Medicina, Pacheco de Melo 3081 (CP1425AU)","place":["Buenos Aires, Argentina"]},{"name":"Departamento de Inmunolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: Current and future perspectives (review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2016.04.007","article-title":"Histamine receptors","volume":"106","author":"Haas","year":"2016","journal-title":"Neuropharmacology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097728","article-title":"Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer","volume":"9","author":"He","year":"2014","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14535","article-title":"Histamine receptors and cancer pharmacology: An update","volume":"177","author":"Massari","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0636-x","article-title":"Study of the antitumour effects and the modulation of immune response by histamine in breast cancer","volume":"122","author":"Nicoud","year":"2020","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1369\/00221554221083670","article-title":"Histamine H4 receptor expression in triple-negative breast cancer: An exploratory study","volume":"70","author":"Speisky","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0173-z","article-title":"Immunomodulatory role of histamine H4 receptor in breast cancer","volume":"120","author":"Sterle","year":"2019","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: Implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06752-9","article-title":"Harnessing the immune system against cancer: Current immunotherapy approaches and therapeutic targets","volume":"48","author":"Kumar","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-023-02677-2","article-title":"Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition","volume":"42","author":"Saha","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: The history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1039\/an9729700142","article-title":"An improved colour reagent for the determination of blood glucose by the oxidase system","volume":"97","author":"Barham","year":"1972","journal-title":"Analyst"},{"key":"B14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: Function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/MB:25:1:19","article-title":"The Fas\/Fas ligand system and cancer: Immune privilege and apoptosis","volume":"25","author":"Abrahams","year":"2003","journal-title":"Mol Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV119.007624","article-title":"Metabolite sensing and signaling in cancer","volume":"295","author":"Wang","year":"2020","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: Insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020275","article-title":"The crosstalk between GPR81\/IGFBP6 promotes breast cancer progression by modulating lactate metabolism and oxidative stress","volume":"11","author":"Longhitano","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-021-00595-3","article-title":"Lactate dehydrogenases amplify reactive oxygen species in cancer cells in response to oxidative stimuli","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202500011","article-title":"Development of potent type V MAPK inhibitors: Design, synthesis, and biological evaluation of benzothiazole derivatives targeting p38\u03b1 MAPK in breast cancer cells","volume":"358","author":"Zoatier","year":"2025","journal-title":"Arch Pharm (Weinheim)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153746","article-title":"The apolipoprotein C1 is involved in breast cancer progression via EMT and MAPK\/JNK pathway","volume":"229","author":"Zhang","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2018.03.014","article-title":"Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer","volume":"424","author":"Fern\u00e1ndez-Nogueira","year":"2018","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70055","article-title":"Differentiation of cytotoxic CD8+ T cell subsets under tumor progression: Can CD69 be a new therapeutic target","volume":"116","author":"Koyama-Nasu","year":"2025","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081232","article-title":"Pathophysiological roles of histamine receptors in cancer progression: Implications and perspectives as potential molecular targets","volume":"11","author":"Nguyen","year":"2021","journal-title":"Biomolecules"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00961.x","article-title":"Histamine receptors and cancer pharmacology","volume":"161","author":"Medina","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12032-024-02437-y","article-title":"The role of histamine and its receptors in breast cancer: From pathology to therapeutic targets","volume":"41","author":"Azimi","year":"2024","journal-title":"Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2165\/11206410-000000000-00000","article-title":"Histamine dihydrochloride: In the management of acute myeloid leukaemia","volume":"71","author":"Yang","year":"2011","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1534735403002001013","article-title":"Histamine dihydrochloride and cancer","volume":"2","author":"Hamill","year":"2003","journal-title":"Integr Cancer Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.071266","article-title":"Paradoxical stimulatory effects of the \"standard\" histamine H4-receptor antagonist JNJ7777120: The H4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity","volume":"79","author":"Seifert","year":"2011","journal-title":"Mol Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2253-6","article-title":"Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1\/PD-L1 checkpoint blockade","volume":"68","author":"Grauer Wiktorin","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402991","article-title":"Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase","volume":"194","author":"Martner","year":"2015","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume":"1248","author":"Zhang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_23","article-title":"Therapeutic development of immune checkpoint inhibitors","volume":"1248","author":"Wang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: Basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602655","article-title":"Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1\/2) in breast cancer","volume":"92","author":"Milde-Langosch","year":"2005","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/bs.apcsb.2019.09.004","article-title":"Interplay between inflammation and cancer","volume":"119","author":"Khandia","year":"2020","journal-title":"Adv Protein Chem Struct Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2373325","article-title":"Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy","volume":"16","author":"McCue","year":"2024","journal-title":"MAbs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0063","article-title":"IL-10 in cancer: An essential thermostatic regulator between homeostatic immunity and inflammation - a comprehensive review","volume":"18","author":"Rallis","year":"2022","journal-title":"Future Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201300004","article-title":"Pegylated IL-10 induces cancer immunity: The surprising role of IL-10 as a potent inducer of IFN-\u03b3-mediated CD8(+) T cell cytotoxicity","volume":"35","author":"Mumm","year":"2013","journal-title":"Bioessays"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101433","article-title":"Lactate exposure shapes the metabolic and transcriptomic profile of CD8+ T cells","volume":"14","author":"Barbieri","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-022-32521-8","article-title":"Lactate increases stemness of CD8+ T cells to augment anti-tumor immunity","volume":"13","author":"Feng","year":"2022","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.10.005","article-title":"Lactic acid and lactate: Revisiting the physiological roles in the tumor microenvironment","volume":"43","author":"Apostolova","year":"2022","journal-title":"Trends Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:51Z","timestamp":1776749631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1770957"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1770957","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1770957"}}